Intensity Therapeutics, Inc. INTS 深 沪
交易中 04-01 10:14:17 美东时间
5.8095
-0.070
-1.20%
华盛通- 最 高5.915
- 今 开5.88
- 成交量 1904股
- 最 低 5.8095
- 昨 收 5.88
- 总市值 1475.91万
- 52周最高 49.9975
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 4.6325
- 委 比 -81.82%
- 总股本 254.05万
- 历史最高 286.00
- 量 比 1.52
- 振 幅 1.79%
- 历史最低 4.6325
- 每 手 1
- 风险率 10.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Intensity Therapeutics Q4 EPS $(1.31) Misses $(0.04) Estimate
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.04) by 2946.51 percent. This is a 76.18 percent increase over losses of $(5.50) per
03-28 04:18
Intensity Therapeutics Issued New U.S. Patent Entitled 'A Method of Treating Cancer'
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent,
03-24 20:09
Intensity Therapeutics Expands ATM Offering Capacity To $60M; May Issue Up To $60M Of Common Stock Under Offering Agreement
Other EventsOn March 23, 2026, Intensity Therapeutics, Inc. (the "Company") filed a prospectus supplement to increase the capacity of its existing "at-the-market" offering program (the "ATM") to $60.0 million. While this
03-24 04:03
BUZZ-U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies
BUZZ-U.S. STOCKS ON THE MOVE-SciSparc, Natera, US energy companies Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 12 (Reuters) - Wall Street's main indexes were set to ope
03-12 21:20
BUZZ-Intensity Therapeutics rises as breast cancer drug shows early promise
BUZZ-Intensity Therapeutics rises as breast cancer drug shows early promise ** Shares of biotech firm Intensity Therapeutics INTS.O rise about 3.5% to $8.19 premarket ** Co says its experimental drug, INT230-6, showed encouraging early results in a small study in triple-negative breast cancer - an a
03-12 19:40
Intensity Therapeutics reports 71% pCR in INT230-6 arm and 44% fewer grade 3+ adverse events in INVINCIBLE-4 study
Intensity Therapeutics reports 71% pCR in INT230-6 arm and 44% fewer grade 3+ adverse events in INVINCIBLE-4 study Intensity Therapeutics reported preliminary Phase 2 INVINCIBLE-4 data in presurgical triple-negative breast cancer showing a pathological complete response (pCR) rate of 71% (5/7) in pa
03-12 19:31
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
SHELTON, Conn., March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery...
03-06 20:47
What's Going On With Intensity Therapeutics Stock Friday?
Intensity Therapeutics slid Friday after announcing a 1-for-25 reverse split effective Feb. 18 to regain Nasdaq bid-price compliance.
02-14 01:28
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers American Well (NYSE:AMWL) stock moved upwards by 31.2% to $5.68 during...
02-14 01:05
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk
BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were muted on Friday, with communication services weighing as
02-13 23:38
